Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy

Transplantation and Cellular Therapy(2023)10.1016/j.jtct.2023.09.027Source: DataRank Database

Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy is a research paper published in Transplantation and Cellular Therapy (2023). On theSindex it has a DataRank of 0.442. It has been cited 18 times.

N/A

0.442DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 2.05)OA: greenTopics (45)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.442

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (18)

David Nemirovsky ORCID,Sean M. Devlin ORCID,Susan DeWolf ORCID,Roni Tamari ORCID,Parastoo B. Dahi ORCID

Live enrichment

PubMed:37806446 PMC:PMC11220618 OpenAlex:https://openalex.org/W4387409048

National Institutes of Health

Grant: P01 CA23766

National Cancer Institute

Grant: P30 CA008748

NCI NIH HHS

Grant: P01 CA023766

NCI NIH HHS

Grant: P50 CA254838

FWCI

2.05

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

greenLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11220618/pdf/nihms-1936301.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2666636723015804?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636723015804?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11220618

Fields of Study

CAR-T cell therapy researchSARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impactsAdultHumansSARS-CoV-2COVID-19COVID-19 VaccinesCOVID-19 Drug TreatmentCOVID-19 TestingRNA, ViralReceptors, Chimeric AntigenRetrospective StudiesHematopoietic Stem Cell TransplantationSARS-CoV-2 variants

MeSH Terms

Receptors, Chimeric AntigenCOVID-19SARS-CoV-2COVID-19 VaccinesCOVID-19 TestingCOVID-19 Drug TreatmentAdultHumansRetrospective StudiesRNA, ViralHematopoietic Stem Cell Transplantation

Keywords

MedicineHematopoietic stem cell transplantationInterquartile rangeOdds ratioTransplantationInternal medicineChimeric antigen receptorCoronavirus disease 2019 (COVID-19)TocilizumabImmunologyDiseaseCancerImmunotherapyInfectious disease (medical specialty)VaccinationSerologic ResponseCovid-19 InfectionCovid-19 TherapyHct And Car-t Patients

Sustainable Development Goals

SDG 0: Good health and well-being